Exemptia 40mg Injection

Exemptia 40mg Injection

Prescription requiredRx Required
Refrigerated 2–8°C · Online payment only

Salt Composition: Adalimumab

Expiry Date: 01/2028

Special offer

Buy at $105.88

$105.88

Inclusive of all taxes

▼

1 injection

About The Product


  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Crohn's Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Juvenile Idiopathic Arthritis
  • Uveitis
  • Hidradenitis Suppurativa

Exemptia 40mg Injection contains the active ingredient Adalimumab, which is an immunosuppressant. This injection is prescribed to treat various conditions such as  ulcerative colitis, crohn’s disease, psoriasis, ankylosing spondylitis, rheumatoid arthritis, etc.

Adalimumab 40mg works by blocking the action of chemical messengers, which are responsible for inflammation, swelling, and redness associated with certain joint diseases. Before starting treatment, inform your physician if you have a history of heart, liver, and kidney disease. Do not self-administer it.

Uses

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Crohn's Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Juvenile Idiopathic Arthritis
  • Uveitis
  • Hidradenitis Suppurativa​

Side Effects

​Exemptia 40mg Injection can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stay for a prolonged period of time.

Common side effects include:

  • Injection site reactions

  • Rash

  • Headache

  • Sinusitis

  • Upper respiratory infections

  • Fever

Serious side effects include:

  • Heart problems

  • Abnormal heartbeat

  • Severe skin reactions

  • Abnormal blood count values

  • Liver injury

  • Bone problems

  • Infections (tuberculosis)

Dosage and Administration

  • ​The recommended dose of Exemptia 40mg Injection may vary according to the type of disease, as well as age, weight, and other health factors of the patients.
  • It should be given under the skin (subcutaneously) by a doctor or experienced nurse.
  • Don't self-administer the injection, and don't double the dose to compensate for the missed dose.​

Safety Advice

Alcohol

It is unclear whether consuming alcohol with Exemptia Injection is safe. Please consult your doctor for guidance.

Pregnancy

Exemptia can be used during pregnancy under strict medical supervision, since its safety in pregnancy has not been fully established. Please consult your doctor for guidance.

Breastfeeding

Consult your doctor regarding the intake of Exemptia, as the effects of this injection on breastfeeding are not clear.

Driving

Exemptia Injection may cause dizziness or weakness due to changes in blood pressure. Do not drive if these symptoms occur. Exemptia Injection may cause a room-spinning sensation and vision disturbances. This may affect your driving ability.

Kidney

Do not take Exemptia 40mg injection without a doctor's consultation in case of kidney problems.

Liver

Share your medical history with the doctor in case of liver disease before taking Exemptia 40mg injection.

Missed Doses

  • If you miss a dose, contact your health professional as soon as possible.
  • Try not to miss or skip your dosage of Exemptia injection.

FAQs

Exemptia 40mg Injection is used for the treatment of various conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease, and ulcerative colitis.

References

  • Navarro‐Sarabia, F., Ariza‐Ariza, R., Hernandez‐Cruz, B., & Villanueva, I. (2005). Adalimumab for treating rheumatoid arthritis. The Cochrane Database of Systematic Reviews, 2005(3), CD005113.
  • Lapadula, G., Marchesoni, A., Armuzzi, A., Blandizzi, C., Caporali, R., Chimenti, S., ... & Salvarani, C. (2014). Adalimumab in the treatment of immune-mediated diseases. International Journal of Immunopathology and Pharmacology, 27(1_suppl), 33-48.
  • Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., ... & Wolbink, G. J. (2007). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the rheumatic diseases, 66(7), 921-926.
  • Kapoor, S., Kaushik, V. K., Jain, R., Rao, V. K. R., Gharia, M., et al. (2019). Real‑life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: Adalimumab Biosimilar Patient Registry data. ACR Open Rheumatology, 1(8), 480–484 - https://doi.org/10.1002/acr2.11067
  • Midha, Y., Kumar, N., Singhal, S., et al. (2023). Efficacy and safety of Exemptia™ (biosimilar adalimumab) in moderate-to-severe steroid-refractory ulcerative colitis: 24-week follow-up in a real-world setting. Biologics: Targets & Therapy (retrospective analysis). Patil, S. (2018). Low‑dose adalimumab biosimilar (ZRC‑3197) in the treatment of hidradenitis suppurativa. Indian Journal of Dermatology, Venereology and Leprology, 84(5), 745–747.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026